Chronic Myeloid Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Radotinib May Yield Superior Outcomes to Imatinib in Newly ... - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Radotinib May Yield Superior Outcomes to Imatinib in Newly ... 
Cancer Therapy Advisor
Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.

and more » 


Chronic Myelocytic Leukemia Pipeline Market (CML, Chronic Myeloid Leukemia) Review, H2 2017 - Medgadget (blog)



Chronic Myelocytic Leukemia Pipeline Market (CML, Chronic Myeloid Leukemia) Review, H2 2017 
Medgadget (blog)
The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and ...

 


Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017 - Research and Markets - Business Wire (press release)



Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017 - Research and Markets 
Business Wire (press release)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with ...

and more » 


Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults - Oncology Nurse Advisor



Oncology Nurse Advisor
 
Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults 
Oncology Nurse Advisor
Arterial thrombotic events (ATEs) appear to occur in only 8.7% of patients with chronic myeloid leukemia (CML) treated with first-line nilotinib. However, in patients with CML who are older than 64 years, the relative risk of ATEs was found to be 6.7 ...

 


Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Imatinib Effective as Front-line Therapy for Pediatric Chronic Myeloid Leukemia 
Cancer Therapy Advisor
First-line imatinib is effective and safe among pediatric patients with chronic myeloid leukemia (CML), according to a study being presented at the 2017 American Society of Hematology Annual Meeting (ASH) in Atlanta, Georgia.1. For the prospective CML ...

and more » 


Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care - AJMC.com Managed Markets Network



Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care 
AJMC.com Managed Markets Network
Tyrosine kinase inhibitors (TKIs) have come a long way in the treatment of chronic myelogenous leukemia (CML), so much so that survival in this patient population can be compared with the healthy population. However, recent findings on adverse events ...

 


Bio-Rad releases first CE-IVD digital PCR test for monitoring chronic myeloid leukemia response to therapy - EurekAlert (press release)



Bio-Rad releases first CE-IVD digital PCR test for monitoring chronic myeloid leukemia response to therapy 
EurekAlert (press release)
December 4, 2017 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announces the launch of the QXDx BCR-ABL %IS Kit, the first CE-IVD digital PCR test that can monitor the molecular response of patients with chronic myeloid leukemia (CML) to ...

 


Dasatinib Approved to Treat Chronic Myeloid Leukemia in Pediatric Patients - Specialty Pharmacy Times



Cancer Therapy Advisor
 
Dasatinib Approved to Treat Chronic Myeloid Leukemia in Pediatric Patients 
Specialty Pharmacy Times
?While chronic myeloid leukemia is rare in children, accounting for less than 3% of all pediatric leukemias, it is often more aggressive in younger patients than in adults and until recently, there have been few available treatment options,? said ...
Sprycel Approved for Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Managed Care magazine
FDA Approves Dasatinib for Pediatric Philadelphia Chromosome-positive CML Cancer Therapy Advisor
FDA Expands Approval Of Bristol-Myers Squibb Myeloid Leukemia Treatment Pharmaceutical Processing
Oncology Nurse Advisor  -The Pharma Letter 
all 6 news articles » 


Mastocytosis Becomes a 'Disease You Don't Want to Miss' - Medscape



Medscape
 
Mastocytosis Becomes a 'Disease You Don't Want to Miss' 
Medscape
There are an estimated 2000 mastocytosis cases per year in the United States, which is about half that for chronic myeloid leukemia, but he suggests that this is an underestimate, as the disease is often unrecognized, and is certainly underdiagnosed ...

 


Chronic Myelogenous Leukemia Treatment Market Value to Reach US$ 8550.8 Million by the end of 2026 ... - PR Newswire (press release)



Chronic Myelogenous Leukemia Treatment Market Value to Reach US$ 8550.8 Million by the end of 2026 ... 
PR Newswire (press release)
Majorly, chronic myelogenous leukemia (CML) occurs in adults, however, it sometimes occurs in children as well. However, targeted drugs called Tyrosine-Kinase Inhibitors (TKIs) have been effective in providing long-term survival rates. Meanwhile, the ...

and more »